Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting

S. Birklé (1) , A. Desselle (1) , T. Chaumette (1) , M.-H. Gaugler (2) , D. Cochonneau (2) , J. Fleurence (2) , N. Dubois (2) , P. Hulin , J. Aubry , F. Paris

1 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
2 IRSN - Institut de Radioprotection et de Sûreté Nucléaire

Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models. © 2013 Landes Bioscience.

Domaines: Sciences du Vivant [q-bio]

S. Birklé, A. Desselle, T. Chaumette, M.-H. Gaugler, D. Cochonneau, et al.. Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting. OncoImmunology, 2013, 2 (4), pp.e23661. ⟨10.4161/onci.23661⟩. ⟨hal-02733859⟩